Please assess the completion status of the following clinical trial:

Trial Title: Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to study specific procedures.~* Premenopausal, regularly menstruating women.~* Age ≥18 years.~* Body weight between 50 and 90 kg.~* Haemoglobin ≥115 g/L.~* Iron deficiency at screening defined as follows:~* S-ferritin level \<50 ng/mL, AND, TfS \<20%, OR,~* S-ferritin level \<15 ng/mL.~* Serum C-reactive protein:~* \<5 mg/L if not on oral contraception, OR,~* \<20 mg/L if use of oral contraception.~* Minimum total score of 5 on the Piper Fatigue Scale (PFS) (mean of items 2 to 23).~* Negative pregnancy test (serum human chorionic gonadotropin (hCG) at screening.~* Normal levels of vitamin B12 and folic acid at screening.~* Adequate contraception during the study period and for 1 month following study completion.~* Availability and willingness to complete all study visits and procedures per protocol.~Exclusion Criteria:~* Haemoglobin level \<115 g/L.~* Haemoglobinopathy.~* Haemochromatose.~* Major depressive disorder based on Patient Health Questionnaire (PHQ-9) (5 items with scores ≥2; one of which corresponds to question number 1 or 2).~* Any active or unstable concurrent medical condition (e.g., cancer, renal dysfunction, liver dysfunction (aspartate aminotransferase (AST); alanine aminotransferase (ALT) \>3-fold upper limit), angina (Class IV).~* Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection.~* Chronic inflammatory disease (e.g., rheumatoid arthritis; inflammatory bowel disease).~* Documented history of clinically significant level of sleep apnoea defined as 5 or more episodes per hour of any type of apnoea.~* Intake of concurrent medications that could interfere with physical or mental performance (e.g., antidepressive, antihistamines, narcotic or any chemotherapeutic agents known to cause drowsiness).~* Important recent weight loss (\>10% within the past month).~* Body weight \<50 kg or \>90 kg.~* Thyroid dysfunction, thyroid stimulating hormone \>4 μU/mL.~* Intake of iron preparations 4 weeks prior to screening.~* Use of gestagens e.g., Implanon, Mirena, Depo-Provera for menstruation repression (see Section 7.7, Prohibited Therapy or Concomitant Treatment, page 35).~* Known hypersensitivity to FCM or to any other iron preparation.~* Pregnancy (positive hCG test at screening) or breast feeding.~* Participation in any other interventional trial within 4 weeks prior to screening.~* Inability to fully comprehend and/or perform study procedures or provide written consent in the Investigator's opinion.~* Subject is not using adequate contraceptive precautions during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner.~* Subject previously has entered this study.~* Subject will not be available for follow-up assessments.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject (Type: EXPERIMENTAL): None
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).